Biossil
Biossil is an AI native biopharma company that advances late-stage programs for life-threatening diseases.
$153M ·
Led by OpenAI Startup Fund · Source: The Globe and Mail
Total raised: $156.7M across 2 sourced rounds
All 2 rounds ↓Signals
Website registeredMay 21, 2023 (3 years old)
About Biossil
It uses an applied AI drug discovery platform to create specialized treatments for distinct patients. Biossil brings resuscitated drugs to market and expands its capacity for clinical development.
Funding rounds
| Date | Round | Amount | Lead | Source |
|---|---|---|---|---|
| Round | $153M | The Globe and Mail | ||
| Seed | $3.7M | fundraisingfox.com |
Timeline
- Website created
Team
AM
Anthony Mouchantaf Chief Executive OfficerKK
Kevin Kuo Head of Medical
Investors
AAbu Dhabi Investment Council
DDuke University
FFounders Fund
GGolden Ventures
MModern Capital
OOpenAI Startup Fundlead investor
PPanache Ventures
QQuiet Capital
SStaircase Ventureslead investor
Companies like Biossil
FF2G$100M Series B+ · Sep 2024
CClaris Bio$118M Series B+ · Jul 2026
AAtlas Bio$12.5M Seed · Oct 2026QQubit PharmaceuticalsSeed · Jun 2022
CCentauri Therapeutics$32.3M Series A · Feb 2026FFountain Life$18M Series B+ · Aug 2025
Other companies backed by OpenAI Startup Fund
HHarvey$550M Series B+ · Sep 2026
AAdaptive Security$81M Series B+ · Dec 2025
KKick$20M Series A · Nov 2025
VValthos$30M Seed · Oct 2025
EEndex$14M Seed · Aug 2025
UUnify$40M Series B+ · Jul 2025
OpenAI Startup Fund portfolio →
Sources and API
Every amount links to the page it came from. * Estimated from an accelerator's published standard deal, not a company-specific disclosure. How Recent Funding sources and verifies funding data. The same data as JSON: /api/v1/companies/biossil (get a free API key).